Haemonetics Corporation
Health
Performance
7.6
Risk
Sell
Buy
Curious about the Scores? Learn more.

Haemonetics Corporation stock rating and score history

All changes in ratings, performance and outlook tracked over time.

15.01.2026
Almost falling apart. Core metrics remain shaky and unstable.
11.01.2026
Momentum tanked. Clearly underperforming.
10.11.2025
Off life support. Still risky, but slightly less scary.
20.08.2025
Climbing out. Risks fading, but not out of the woods.

Haemonetics Corporation stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Haemonetics Corporation do? Business model and key facts

Get the full picture of Haemonetics Corporation: what it builds, where it operates, and how it makes money.

Haemonetics Corporation Profile

Sector: Healthcare

Industry: Medical - Instruments & Supplies

Employees (FY): 3657

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

shop
Company facts
Christopher A. Simon
CEO
3657
Employees worldwide
shop
Performance
-1.4%
Last 12 months
-41.13%
Last 5 years
shop
Growth
$1,36B
Revenue year
$167,68M
Net income
shop
Valuation
$3,57B
Market Cap
18.97
Price/Earnings Ratio

Stocks related to Haemonetics Corporation

Selected based on industry alignment and relative market positioning.

ICUI
ICU Medical, Inc.
156.31
+0.77%
5.7
Sell
Buy
ICU Medical, Inc.
TFX
Teleflex Incorporated
103.29
-1.26%
6.9
Sell
Buy
Teleflex Incorporated
MMSI
Merit Medical Systems, Inc.
81.46
+1.38%
5.1
Sell
Buy
Merit Medical Systems, Inc.
WRBY
Warby Parker Inc.
28.00
-1.16%
8.7
Sell
Buy
Warby Parker Inc.
XRAY
DENTSPLY SIRONA Inc.
12.32
-2.06%
6.6
Sell
Buy
DENTSPLY SIRONA Inc.

Haemonetics Corporation fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.